BIOTECH CATALYST AI SCANNER — July WK1

This week's slate is short, and the reason is mechanical rather than a lack of opportunity. The scanner only surfaces catalysts dated at least seven days forward from the scan date, and no more than 45 days out — a 7-to-45-day forward window. Anything with a fundamental deadline at the end of June, or earlier in Q2/H1 2026, has already passed inside that seven-day buffer and drops out of view. A large cluster of names with end-of-June and early-July deadlines sits right inside that excluded zone this issue, which is why you're seeing a thinner, decision-heavy list instead of the usual mix — not a quiet market.

What did clear the window is unusually decision-grade. Seven of the ten featured names carry hard regulatory dates — PDUFA and generic-drug actions for Celcuity, Capricor, Vera, Moderna, Outlook, NRx, and MannKind — clustered between July 7 and August 5. That concentration matters: binary regulatory events compress risk and reward into a single day, and this stretch has an unusual number of them back to back.

The remainder splits between cash-pressured conference readouts (Seres, Cadrenal, Satellos), where the data is real but financing is the gating risk, and one early efficacy look (argenx's empasiprubart). Read the BSI spread accordingly — the top tier (Celcuity 8.8, Seres 8.2) reflects genuinely strong setups, while the conference-presentation names lower down carry softer, signal-stage data despite respectable scores.

What We're Tracking:

Trading Below Cash: None flagged this week
Cash Pressure: MCRB, CVKD, OTLK, MSLE, BIIB
Initial Data: ARGX
Multi-Catalyst: MSLE, COAG

FEATURED

#1. CELC — Celcuity Inc.

THE CATALYST
Event: Gedatolisib + fulvestrant (VIKTORIA-1) — PDUFA Regulatory Decision in HR+/HER2-, PIK3CA wild-type advanced breast cancer
Date: Jul 17, 2026
FDA Status: BTD, FTD
BSI: 8.8/10

Celcuity is a Minneapolis oncology developer whose lead regimen is licensed from Pfizer under a deal carrying development milestones. Heading into the July 17 decision it has been visibly preparing to run as a commercial company — an upsized convertible note raise in June, plus a new equity-incentive plan and expanded ESPP approved by shareholders. With $817M in the bank, financing isn't the question here; execution into a launch is.

📈 The Setup: For HR+/HER2- patients whose disease progresses after a CDK4/6 inhibitor and endocrine therapy, the targeted options thin out fast — and those without a PIK3CA mutation are shut out of the PI3K-alpha and AKT inhibitors (alpelisib, capivasertib) that need a tumor alteration to work, leaving everolimus or chemotherapy. Gedatolisib is an intravenous pan-PI3K/mTORC1/2 inhibitor (it blocks every class I PI3K isoform plus both mTOR complexes rather than a single node), and VIKTORIA-1 tested it precisely in that underserved PIK3CA wild-type group (N=392). The gedatolisib-palbociclib-fulvestrant triplet delivered median progression-free survival of 9.3 months versus 2.0 for fulvestrant alone (HR 0.24), and the gedatolisib-fulvestrant doublet reached 7.4 months (HR 0.33) — both highly significant. Grade ≥3 hyperglycemia (dangerously elevated blood sugar) stayed low at 2.3%, though the triplet's neutropenia (62%, largely from added palbociclib) and stomatitis are the toxicities to watch. This is a fortress setup: cash-rich, Phase 3 data in hand, and a clean July 17 PDUFA rather than an early signal.

✅ The Edge: It targets the PIK3CA wild-type population that has no PI3K-pathway option today — alpelisib and capivasertib both require a tumor alteration these patients don't carry — and the triplet's HR of 0.24 against fulvestrant is an unusually large effect in a post-CDK4/6 setting where everolimus and chemo are the fallback.

⚠️ The Risk: It's an IV regimen entering a market built around oral pills, and the headline benefit rides the three-drug combination, which carries heavy neutropenia from added palbociclib. The fulvestrant-monotherapy control sets a low bar (2.0-month PFS) — a comparator choice reviewers and clinicians may weigh when judging the real-world magnitude.

#2. MCRB — Seres Therapeutics Inc.

THE CATALYST
Event: SER-155 — Phase 2 Conference Presentation in allogeneic stem-cell transplant
Date: Mid-2026 (Est.)
FDA Status: BTD, FTD
BSI: 8.2/10

Cambridge-based Seres builds live bacterial therapeutics for immune and inflammatory disease. It sold VOWST — its first approved microbiome drug — to Nestlé Health Science in 2024, and a June 2026 amendment pulled forward $25M in milestone payments. But the company cut roughly 30% of staff in February and paused unfunded programs, and its long-standing collaboration with Memorial Sloan Kettering is the engine behind the upcoming data. With about 2.5 months of runway, the clock is the story.

📈 The Setup: There is no approved microbiome therapy for preventing bloodstream infections in stem-cell transplant patients — standard care is broad-spectrum antibiotics and supportive measures. SER-155 is an oral consortium of 16 cultivated bacterial strains designed to crowd out gut pathogens, shore up the intestinal barrier, and tune immune response. The randomized Phase 1b Cohort 2 (n=34 evaluable) was striking: bloodstream infections fell to 10% from 42.9% on placebo (p=0.04) and systemic antibiotic days dropped from 21.1 to 9.2. The mid-2026 readout is a conference presentation from an MSKCC investigator trial in a related immunocompromised group (checkpoint-inhibitor colitis), not a pivotal company trial — so treat it as signal-building, not definitive. Vedanta's VE303 sits earlier-stage and targets C. difficile, a different setting entirely.

✅ The Edge: The Phase 1b infection reduction (10% vs 42.9%) is a large, statistically significant effect in a setting with no microbiome competitor, and the program already holds Breakthrough and Fast Track designations.

⚠️ The Risk: The Phase 2 is unfunded. Even a clean July readout doesn't start enrollment without fresh capital or a partner — and with 2.5 months of runway against a $69M cap, that financing need is immediate and dilutive.

#3. CVKD — Cadrenal Therapeutics Inc.

THE CATALYST
Event: CAD-1005 — Phase 3 Conference Presentation in heparin-induced thrombocytopenia (HIT)
Date: Jul 12, 2026
FDA Status: FTD, ODD
BSI: 7.7/10

Cadrenal Therapeutics, based in Ponte Vedra, Florida, works on 12-lipoxygenase inhibition for thrombotic and immune conditions. It picked up the 12-LOX portfolio in December 2025 and, after an end-of-Phase-2 FDA meeting, is steering CAD-1005 toward pivotal Phase 3 in HIT while floating expansion into cardiac-surgery kidney injury and shopping for partners at BIO 2026. The balance sheet is the glaring problem: negative cash and effectively no runway into the data.

📈 The Setup: Heparin-induced thrombocytopenia is an immune reaction in which heparin triggers platelet activation and dangerous clotting; today's standard — direct thrombin inhibitors like argatroban and bivalirudin — cuts thrombin but leaves new-clot rates high. CAD-1005 is a first-in-class oral 12-LOX inhibitor (it blocks platelet immune activation downstream of the FcγRIIA receptor), targeting the immune driver itself rather than thrombin generation. In a randomized, blinded, placebo-controlled Phase 2, adding it to standard anticoagulation produced a greater-than-25% absolute reduction in thrombotic events versus placebo. The July 12 ISTH presentation is billed as the first randomized controlled data ever generated in HIT — genuinely novel — but it's a conference readout of Phase 2, not a registrational result, and the company has to fund an entire global Phase 3 from a standing start.

✅ The Edge: No approved therapy targets the immune mechanism behind HIT — CAD-1005 stands alone in late-stage development as a disease-modifying add-on, with Fast Track and Orphan Drug designations and a >25% absolute event reduction to point to.

⚠️ The Risk: Zero cash runway against the cost of a global Phase 3 in a rare, acute indication. The FDA hasn't confirmed the pivotal endpoint or statistical assumptions, and HIT registration precedent is thin — capital has to come first, and it comes from a $9M base.

#4. CAPR — Capricor Therapeutics Inc.

THE CATALYST
Event: Deramiocel (CAP-1002) — PDUFA Regulatory Decision in Duchenne muscular dystrophy (DMD)
Date: Jul 29, 2026
FDA Status: ODD
BSI: 7.1/10

San Diego's Capricor develops cell and exosome therapies for rare disease, led by deramiocel in Duchenne. The wrinkle is its own commercial partner: Capricor sued Nippon Shinyaku/NS Pharma in May 2026 over pricing terms it argues could choke off Medicare and Medicaid access and stall launch prep, even though NS Pharma holds exclusive US/Japan rights. The company enters the July 29 decision off positive five-year HOPE-2 extension data and HOPE-3 Phase 3 results, with an FDA advisory committee now scheduled.

📈 The Setup: Duchenne care is increasingly crowded — Sarepta's Elevidys gene therapy sets the efficacy bar for ambulatory boys, and exon-skipping drugs plus givinostat cover subsets — but most of it depends on specific mutations or viral vectors. Deramiocel is an allogeneic cardiosphere-derived cell therapy working through paracrine signaling (the cells secrete factors that calm inflammation and fibrosis), and crucially it's mutation-agnostic and aimed at the cardiomyopathy that ultimately kills DMD patients. HOPE-2's five-year extension showed sustained skeletal and cardiac benefit versus natural history, and HOPE-3 (n=106, double-blind) hit its primary endpoints on arm and heart function. The catalyst itself is pivotal — a BLA decision with an Ad Com — but it follows a prior complete response letter, so data sufficiency is the live question.

✅ The Edge: It's the only mutation-agnostic cell therapy under BLA review specifically for DMD cardiomyopathy, with multi-year dual-tissue durability data no competitor has matched — addressing the cardiac failure that Elevidys and exon-skippers don't directly treat.

⚠️ The Risk: A prior CRL flagged efficacy-data sufficiency, and the Ad Com plus a natural-history comparator will decide whether the resubmission clears full approval. Layer on the unresolved NS Pharma lawsuit, which could hamstring distribution and Medicaid access even with a green light.

#5. VERA — Vera Therapeutics Inc.

THE CATALYST
Event: Atacicept (ORIGIN 3) — PDUFA Regulatory Decision in IgA nephropathy
Date: Jul 07, 2026
FDA Status: BTD
BSI: 7.0/10

Brisbane, California-based Vera Therapeutics develops treatments for serious immune-driven disease, with a focus on autoimmune kidney conditions; its lead fusion-protein technology is licensed from Stanford. Atacicept already holds FDA Priority Review, and a June 2026 alignment with the agency pulled the confirmatory eGFR (kidney-function) analysis forward to Q3, setting up an sBLA in Q4 to convert accelerated approval into full approval. With nearly $493M in cash, this is a well-funded run into a July 7 decision.

📈 The Setup: IgA nephropathy already has approved options — Tarpeyo, Filspari, and Fabhalta — so atacicept enters a market that's filling in fast. It's a TACI-Fc fusion protein (a decoy that mops up two cytokines at once, BAFF and APRIL, which together drive the B-cells and IgA production behind the disease). In Phase 3 ORIGIN 3 (N=431), a prespecified interim showed 46% proteinuria reduction from baseline at week 36 — a 42% relative drop versus placebo (p<0.0001) — with placebo-like safety. The differentiator is practical as much as mechanistic: once-weekly self-administered subcutaneous dosing via autoinjector on top of standard ACE inhibitor/ARB therapy. With a near-term PDUFA in hand and strong regulatory momentum this reads as a fortress, though the stock runs in overbought (RSI 88).

✅ The Edge: Atacicept would be the first dual BAFF/APRIL modulator to reach an approval decision in IgAN, ahead of Vertex's povetacicept and Visterra's sibeprenlimab, which remain in development — and the once-weekly autoinjector is a real convenience edge over infused rivals.

⚠️ The Risk: Accelerated approval rests on proteinuria, a surrogate endpoint; the FDA has demanded confirmatory eGFR data in prior IgAN reviews, and that readout is still ahead. Commercially, three approved therapies are already competing for the same patients.

#6. MRNA — Moderna Inc.

THE CATALYST
Event: mRNA-1010 (P304) — PDUFA Regulatory Decision in seasonal influenza, adults 50+
Date: Aug 05, 2026
BSI: 7.0/10

Moderna, out of Cambridge, Massachusetts, builds mRNA vaccines and therapeutics with a respiratory and infectious-disease core. It runs a CEPI partnership on pandemic flu and recently signed a five-year supply-and-tech-transfer MoU with Mexico. The flu program had a rocky regulatory start — the FDA initially refused to file mRNA-1010 — but a Type A meeting and resubmission put it back on track, with parallel filings advancing in the EU, Canada, and Australia.

📈 The Setup: The seasonal flu shot market is entrenched — standard-dose (GSK's Fluarix, Seqirus's Afluria), high-dose (Sanofi's Fluzone HD), and adjuvanted (Fluad) products all compete on reactogenicity and reimbursement. mRNA-1010 encodes hemagglutinin antigens (the surface proteins the immune system learns to recognize) for influenza A and B, and it's the only mRNA flu candidate to reach a BLA decision. The pivotal P304 trial (N>40,000, adults 50+) delivered 26.6% relative efficacy versus standard-dose comparators — clearing the superiority bar — with immunogenicity above licensed vaccines and consistent results across age and comorbidity subgroups. A 9-0 VRBPAC vote backed benefit-risk in both the 50-64 and 65+ cohorts. Coming off 41% momentum into an August 5 decision, this is a frontrunner already pricing in optimism, though the panel did flag subpopulation evidence gaps.

✅ The Edge: It's the sole mRNA influenza vaccine at the approval stage, with a unanimous advisory-committee vote and superiority data over standard-dose shots — and Moderna's existing mRNA manufacturing base gives it scale that rivals' nascent mRNA flu efforts can't match.

⚠️ The Risk: The 65+ approval would ride an accelerated pathway requiring a post-marketing confirmatory trial; any shortfall could bring label limits. And incumbents with lower reactogenicity and locked-in formulary spots can squeeze pricing even after approval.

#7. OTLK — Outlook Therapeutics Inc.

THE CATALYST
Event: LYTENAVA (bevacizumab-vikg) / ONS-5010 — PDUFA Regulatory Decision in wet AMD
Date: Jul 29, 2026
FDA Status: BTD
BSI: 6.9/10

Iselin, New Jersey-based Outlook Therapeutics is commercializing an ophthalmic formulation of bevacizumab for retinal disease. It already launched LYTENAVA in Germany, Austria, and the UK after European approval, and leans on distribution partners Cencora in the US and Mediconsult in Switzerland. The pivotal moment came in May 2026, when an FDA appeal overturned the efficacy objections behind multiple prior Complete Response Letters — clearing the way for the current Class 1 resubmission and the July 29 decision. With under four months of cash, the financing clock is loud.

📈 The Setup: Wet age-related macular degeneration is dominated by branded anti-VEGF drugs — Lucentis, Eylea, Vabysmo — but the real volume leader is off-label compounded Avastin, used because it's cheap. LYTENAVA is an ophthalmic bevacizumab (an antibody that blocks VEGF, the protein driving the leaky blood vessels behind vision loss), pitched as the first FDA-approved, standardized version of exactly that molecule — a regulated alternative to compounding-pharmacy product. NORSE TWO (n=228) beat ranibizumab on vision gains; NORSE EIGHT (~400 treatment-naïve patients) hit non-inferiority at week 12 after missing its week-8 primary. After the appeal cleared the efficacy deficiency, the FDA's Office of New Drugs accepted that the combined data establish substantial evidence — making this a genuinely pivotal decision. But the stock has tripled (131% momentum) into it, and the underlying data package is thin.

✅ The Edge: LYTENAVA would be the only FDA-approved ophthalmic bevacizumab — a regulated, lower-cost option positioned against both branded anti-VEGFs and the compounded Avastin that dominates on price.

⚠️ The Risk: Three prior CRLs, including manufacturing deficiencies, leave room for fresh information requests or label limits even under Class 1 review — and post-approval CMC scale-up is unproven. Against free compounded Avastin, reimbursement and uptake are far from assured.

#8. NRXP — NRx Pharmaceuticals Inc.

THE CATALYST
Event: KETAFREE — Regulatory Decision on a preservative-free IV ketamine formulation
Date: Jul 29, 2026
BSI: 6.8/10

NRx Pharmaceuticals, headquartered in Wilmington, Delaware, builds neuroplastic CNS therapies — for suicidal depression, PTSD, and chronic pain — around an NMDA-receptor platform, paired with its HOPE Therapeutics clinic network running TMS and related care. It manufactures through Nephron Pharmaceuticals in the US and partners with neurocare Group on clinics. Ahead of the July 29 date it began commercial manufacturing batches in May and raised equity in June to extend runway.

📈 The Setup: KETAFREE isn't a new-molecule bet — it's an abbreviated filing (ANDA) seeking approval for a preservative-free, single-patient-vial version of intravenous ketamine, an NMDA-receptor antagonist already used for anesthesia and pain. The whole thesis rests on bioequivalence to the reference drug rather than fresh efficacy trials, and the differentiation is the removal of benzethonium chloride, a preservative the FDA does not recognize as safe and that matters most under repeated dosing. The setup is unusually de-risked for biotech: an FDA Office of Generic Drugs bioequivalence letter in March 2026 reported no deficiencies, registration batches are complete, and the GMP audit cleared — narrowing what's left before the date. This is a focused, single-asset specialist play rather than a broad platform readout. Today's generic multi-dose vials, from multiple suppliers, are the field it has to displace.

✅ The Edge: No approved preservative-free single-patient IV ketamine exists, and the March bioequivalence clearance with "no deficiencies" plus completed GMP work materially lowers approval risk — a clean regulatory runway most micro-caps don't have.

⚠️ The Risk: Commercial pull is the soft spot. Payers and hospital formularies favor the cheapest existing multi-dose generic, so even on approval, uptake may stall without an explicit policy push to switch away from benzethonium-containing vials.

#9. MSLE — Satellos Bioscience Inc.

THE CATALYST
Event: SAT-3247 (TRAILHEAD) — Phase 2 Conference Presentation in Duchenne muscular dystrophy (adult study)
Date: Jul 08, 2026
Additional catalysts: 1 more within 90 days
BSI: 6.4/10

Satellos Bioscience, based in Toronto, develops therapies to restart muscle regeneration in degenerative muscle disease, beginning with Duchenne. It has no major licensing or co-development partner, so it's going it alone. A February 2026 public offering padded the balance sheet ahead of a cluster of 2026 readouts, and in January it brought on a chief development officer who previously handled regulatory work at Vertex.

📈 The Setup: Duchenne is a crowded, well-capitalized field — Sarepta's Elevidys gene therapy, several exon-skipping oligonucleotides, and givinostat are all approved — and Satellos is the contrarian entry. SAT-3247 is an oral AAK1 inhibitor (it targets a kinase to restore the asymmetric division muscle stem cells need to keep producing new muscle), and it's mutation-agnostic, pitched as complementary to dystrophin-focused drugs rather than competing head-on. The data so far are early: a four-patient Phase 1b showed grip-strength gains that held at six months in the open-label extension, with target exposure and a clean safety read in Phase 1a/b. The July 8 ICNMD poster delivers the first durability look from those four TRAILHEAD patients — useful color, but a tiny, early, open-label dataset, not a controlled efficacy result, with a second Phase 2 update (BASECAMP) expected later in the year. Treat this as signal, not proof.

✅ The Edge: SAT-3247 is the only clinical-stage small molecule explicitly designed to restore muscle stem-cell function independent of dystrophin or specific mutations — a genuinely different angle from the gene therapy and exon-skippers that define the space.

⚠️ The Risk: The evidence is thin — four patients, open-label, grip strength rather than the validated NSAA or six-minute-walk endpoints the FDA has required for DMD. Expect requests for confirmatory functional data, and with ~5.5 months of runway, the financing need arrives well before any pivotal answer.

#10. ARGX — argenx SE

THE CATALYST
Event: Empasiprubart (VARVARA) — Phase 2 proof-of-concept Topline Data in delayed graft function (DGF)
Date: Mid-2026 (Est.)
BSI: 6.2/10

argenx, based in Amsterdam and listed on both Euronext Brussels and Nasdaq, is a global immunology company built around antibody therapies for severe autoimmune disease, sourced through its Immunology Innovation Program with academic partners. It has out-licensed select programs to AbbVie, LEO Pharma, and AgomAb, and its commercial engine, VYVGART, is growing strongly — the backdrop for taking shots on earlier-stage bets like this one. Empasiprubart recently advanced into Phase 3 for multifocal motor neuropathy off positive Phase 2 data.

📈 The Setup: There is no approved therapy specifically for delayed graft function — the early failure of a transplanted kidney to work — so management relies on induction immunosuppression and dialysis. Empasiprubart is a "sweeping" antibody (engineered to recycle via FcRn and clear its target repeatedly) that binds complement protein C2, shutting down the classical and lectin immune pathways while sparing the alternative one. In the ongoing VARVARA trial (N≈102 deceased-donor kidney recipients), patients get two IV doses around transplant on top of standard immunosuppression, with kidney function (eGFR) at six months as the primary endpoint. The catch worth stating plainly: prior work confirmed target engagement and tolerability, but no DGF efficacy data exist yet — this mid-2026 readout is the first look. After the program's pivot toward this indication, it's a comeback-style bet on a new use for a known antibody. No direct competitor sits in C2 blockade for transplant.

✅ The Edge: Empasiprubart is the only complement C2 blocker in transplant development, and the 52-week analysis lines the decision up with longer-term eGFR durability — a deeper readout than a one-off incidence signal, backed by a company that can fund a real Phase 3.

⚠️ The Risk: This is first-in-indication efficacy data with no precedent — the FDA has little history with DGF endpoints, and eGFR without a clear link to graft survival could draw demands for more. Even approved, it would have to displace entrenched induction regimens at high-cost transplant centers.

WATCHLIST

#11. MNKD — MannKind Corporation [Cardio-Renal]

Price: $4.14 | Cap: $1.28B | Cash: $128.6M | RSI: 75 | Momentum: +13.7%
FUROSCIX ReadyFlow Autoinjector (SCP-111) — PDUFA Regulatory Decision in CHF/CKD edema (Jul 26, 2026)
BSI: 5.6/10

The Intel: MannKind's pitch is delivery, not molecule — the ReadyFlow autoinjector delivers subcutaneous furosemide (a loop diuretic that flushes excess fluid by blocking sodium reabsorption in the kidney) so heart-failure and kidney patients can dose at home instead of going in for IV diuresis. The catalyst is a genuine PDUFA backed by 70+ months of runway, but the clinical package is light and the device leans on a long-established generic drug. The bet is on convenience adoption versus existing clinic-based and oral diuretic routines, not on efficacy.

#12. BIIB — Biogen Inc. [Neurology]

Price: $216.03 | Cap: $31.89B | Cash: $1.43B | RSI: 69 | Momentum: +10.0%
Diranersen (BIIB080 / CELIA) — Phase 2 Conference Presentation in Alzheimer's disease (Jul 12, 2026)
FTD
BSI: 5.3/10

The Intel: Diranersen takes a different swing at Alzheimer's than the approved amyloid antibodies (Biogen's own Leqembi among them): it's an antisense oligonucleotide (a short synthetic strand that switches off a gene) that lowers tau protein by targeting MAPT mRNA inside neurons. Context matters heading into the July data presentation: the Phase 2 CELIA topline, out in May, missed its primary endpoint — but showed clear reductions in CSF and PET tau plus a signal of slowed cognitive decline, and Biogen is pushing to registrational development anyway. The conference readout is the full dataset behind that mixed result. Commercial upside is enormous if tau-lowering ultimately translates, but a missed primary keeps the bar high.

#13. COAG — Hemab Therapeutics Holdings Inc. [Hematology]

Price: $32.37 | Cap: $1.51B | Cash: $142.4M | RSI: 50 | Momentum: 0.0%
Sutacimig — Phase 2/3 Conference Presentation in Glanzmann thrombasthenia (Jul 11, 2026)
BTD
BSI: 5.1/10

The Intel: Hemab targets rare bleeding disorders, and sutacimig goes after Glanzmann thrombasthenia — an inherited platelet defect — as a subcutaneous bispecific antibody: one arm binds and stabilizes Factor VIIa (a clotting enzyme), the other latches onto TLT-1 on activated platelets, recruiting that enzyme to the platelet surface to help form a clot — a prophylactic alternative to on-demand platelet transfusions. The strong differentiation (no comparable prophylactic exists) and a Breakthrough designation underpin the score, but the July 11 readout is a conference presentation rather than a pivotal result, and a second catalyst sits within 90 days. A healthy ~20-month runway removes near-term financing pressure.

The Strategist's Take

Start with the calendar mechanics, because they shape everything below. The scanner works a 7-to-45-day forward window and only counts catalysts at least a week out. That buffer quietly swept out a wall of end-of-June and early-Q2 deadline names this week — catalysts that are real but fall inside the excluded zone — which is why the slate is shorter and tilted toward hard July regulatory dates rather than the usual mix. It's a timing artifact, not a dry pipeline; expect the window to refill as those deadlines roll forward into range.

On the names themselves, the BSI spread is doing real work this week. Celcuity (8.8) is the standout — a striking Phase 3 PFS benefit (HR 0.24) in PIK3CA wild-type breast cancer with no PI3K-pathway option today, a clean July 17 PDUFA, and $817M in the bank make it about as de-risked as catalyst biotech gets. Vera (7.0) and Moderna (7.0) round out the high-conviction regulatory tier, both backed by strong trial data and, in Moderna's case, a unanimous advisory-committee vote. NRx (6.8) is the quiet one worth a look: an ANDA resting on a clean bioequivalence letter is a structurally different, lower-variance bet than the typical efficacy gamble.

Be honest about the lower half. Several names carry respectable scores on the strength of their setup or balance sheet, but the catalysts themselves are conference presentations, not pivotal readouts — Satellos (6.4) is showing four-patient, open-label grip-strength data, while Biogen's diranersen (5.3) and Hemab's sutacimig (5.1) are abstract-stage updates where prior tau-lowering and rare-disease programs warn against over-reading early signals. And the cash-pressured trio — Seres (2.5 months of runway), Cadrenal (effectively zero), Outlook (under four) — pair genuine data against immediate, dilutive financing needs. Strong data doesn't pay the bills; size those accordingly.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis. Each issue covers catalysts dated roughly 7 to 45 days forward from the scan date — events expected inside the next seven days, or beyond 45 days out, are not included this issue and may appear in a future scan as their dates move into range.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.2 | Generated: 2026-06-27T13:40:47